Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00742209 · ClinicalTrials.gov registry record · Phase 2

Prevention Study in Adult Patients Suffering From Migraine Headaches

A Phase 2 study of Migraine and Migraine Disorders, sponsored by XenoPort.

Completed
Registry status
Phase 2
Development phase
526
Enrollment target
20
Study locations

NCT00742209 is a Phase 2 study of Migraine and Migraine Disorders that has completed, run by XenoPort. The registered enrollment target is 526 participants, above the 353-participant average among 102 other Migraine trials with a reported enrollment target (49% higher). The trial reports 20 study locations across 9 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00742209, a Phase 2 study of Migraine and Migraine Disorders, has completed, sponsored by XenoPort.

COMPLETED
Registry status
Phase 2
Development phase
526 participants
Enrollment target
20
Study locations

Study Summary

Purpose of the study is to evaluate dose response relationship, efficacy, safety and tolerability of target doses of GSK1838262 compared to placebo in the prophylactic treatment of migraine headache. Once subjects complete the baseline and meet the randomization criteria, they will complete a 5-wk flexible titration period and then enter the 12 week maintenance period.

Conditions Studied

Migraine Migraine Disorders

Interventions

  • DRUG Placebo
  • DRUG GSK1838262

Study Locations (20)

California

  • GSK Investigational Site - Anaheim
  • GSK Investigational Site - Newport Beach
  • GSK Investigational Site - Redlands
  • GSK Investigational Site - San Francisco
  • GSK Investigational Site - Santa Monica
  • GSK Investigational Site - Westlake Village

Colorado

  • GSK Investigational Site - Colorado Springs
  • GSK Investigational Site - Colorado Springs
  • GSK Investigational Site - Denver

Florida

  • GSK Investigational Site - DeLand
  • GSK Investigational Site - Sunrise
  • GSK Investigational Site - West Palm Beach

Arizona

  • GSK Investigational Site - Phoenix
  • GSK Investigational Site - Phoenix

Georgia

  • GSK Investigational Site - Atlanta
  • GSK Investigational Site - Stockbridge

Alabama

  • GSK Investigational Site - Birmingham

Illinois

  • GSK Investigational Site - Chicago

Kansas

  • GSK Investigational Site - Wichita

Trial Details

FieldValue
Enrollment Target 526 participants
Start Date 2008-08
Est. Completion 2010-06
Phase Phase 2

Sponsor

XenoPort

19 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT00742209

The ClinicalTrials.gov registry entry for NCT00742209 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 526 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 353-participant average among 102 other Migraine trials with a reported enrollment target (49% higher). The listed sponsor is XenoPort, which has 19 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Migraine appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.

NCT00742209 reports 20 study locations spanning 9 distinct geographic areas - top geographies include California, Colorado, Florida.

Frequently Asked Questions

What is clinical trial NCT00742209 about?

NCT00742209 is a clinical study titled "Prevention Study in Adult Patients Suffering From Migraine Headaches". Purpose of the study is to evaluate dose response relationship, efficacy, safety and tolerability of target doses of GSK1838262 compared to placebo in the prophylactic treatment of migraine headache. Once subjects complete the baseline and meet the randomization criteria, they will complete a 5-wk f...

What is the current status of trial NCT00742209?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 526 participants. The study started on 2008-08. Estimated completion is 2010-06.

What conditions does trial NCT00742209 study?

This clinical trial studies the following conditions: Migraine, Migraine Disorders.

What interventions are being tested in trial NCT00742209?

The interventions under investigation include: Placebo (DRUG), GSK1838262 (DRUG).

Who is sponsoring clinical trial NCT00742209?

This trial is sponsored by XenoPort, which has 19 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00742209 being conducted?

This trial has 20 study locations across Alabama, Arizona, California, Colorado, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Migraine

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Migraine

All registered trials for this condition

Migraine Disorders

All registered trials for this condition

Alabama

All trials with a study site in Alabama

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.